A citation-based method for searching scientific literature

Elizabeth M Wikler, Robert J Blendon, John M Benson. Alzheimers Res Ther 2013
Times Cited: 27







List of co-cited articles
140 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
37

Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
317
37

Public perceptions of presymptomatic testing for Alzheimer disease.
Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
31
37

Public beliefs and knowledge about risk and protective factors for Alzheimer's disease.
J Scott Roberts, Sara J McLaughlin, Cathleen M Connell. Alzheimers Dement 2014
41
29

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
22

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.
Peter J Neumann, Joshua T Cohen, James K Hammitt, Thomas W Concannon, Hannah R Auerbach, Chihui Fang, David M Kent. Health Econ 2012
83
22

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.
Jill S Goldman, Susan E Hahn, Jennifer Williamson Catania, Susan LaRusse-Eckert, Melissa Barber Butson, Malia Rumbaugh, Michelle N Strecker, J Scott Roberts, Wylie Burke, Richard Mayeux,[...]. Genet Med 2011
171
22

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
60
18

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Serena Chao, J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green. Alzheimer Dis Assoc Disord 2008
162
18


Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
28
18

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
50
18

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
35
18

Using AD biomarker research results for clinical care: a survey of ADNI investigators.
Melanie B Shulman, Kristin Harkins, Robert C Green, Jason Karlawish. Neurology 2013
27
14

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.
Robert C Green, Kurt D Christensen, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Charmaine D M Royal, Thomas O Obisesan, Robert Cook-Deegan, Erin Linnenbringer, Melissa Barber Butson,[...]. Alzheimers Dement 2015
25
16

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger, Anne M Fagan, Alison Goate, Nick C Fox, Daniel S Marcus, Nigel J Cairns, Xianyun Xie, Tyler M Blazey,[...]. N Engl J Med 2012
14

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
279
14

Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.
J Scott Roberts, Susan A LaRusse, Heather Katzen, Peter J Whitehouse, Melissa Barber, Stephen G Post, Norman Relkin, Kimberly Quaid, Robert H Pietrzak, L Adrienne Cupples,[...]. Alzheimer Dis Assoc Disord 2003
64
14

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
422
14

Public attitudes about genetic testing for Alzheimer's disease.
P J Neumann, J K Hammitt, C Mueller, H M Fillit, J Hill, N A Tetteh, K S Kosik. Health Aff (Millwood) 2001
70
14

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.
Joshua D Grill, Jason Karlawish, David Elashoff, Barbara G Vickrey. Alzheimers Dement 2013
24
16



Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
L A Farrer, L A Cupples, J L Haines, B Hyman, W A Kukull, R Mayeux, R H Myers, M A Pericak-Vance, N Risch, C M van Duijn. JAMA 1997
14

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
31
14

Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.
Craig W Ritchie, José Luis Molinuevo, Luc Truyen, Andrew Satlin, Serge Van der Geyten, Simon Lovestone. Lancet Psychiatry 2016
118
14

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
36
14

Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction.
Silke Schicktanz, Mark Schweda, Jesse F Ballenger, Patrick J Fox, Jodi Halpern, Joel H Kramer, Guy Micco, Stephen G Post, Charis Thompson, Robert T Knight,[...]. Front Hum Neurosci 2014
15
26

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
20
20

Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Jeffrey L Cummings, Steven T Dekosky, Pascale Barberger-Gateau, André Delacourte, Giovanni Frisoni, Nick C Fox, Douglas Galasko,[...]. Lancet Neurol 2010
11


Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis.
David G Le Couteur, Jenny Doust, Helen Creasey, Carol Brayne. BMJ 2013
120
11


Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. J Nucl Med 2013
153
11



Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Michael Grundman, Michael J Pontecorvo, Stephen P Salloway, P Murali Doraiswamy, Adam S Fleisher, Carl H Sadowsky, Anil K Nair, Andrew Siderowf, Ming Lu, Anupa K Arora,[...]. Alzheimer Dis Assoc Disord 2013
89
11

Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
23
13

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Clifford R Jack, David S Knopman, William J Jagust, Leslie M Shaw, Paul S Aisen, Michael W Weiner, Ronald C Petersen, John Q Trojanowski. Lancet Neurol 2010
11

Postgenomics, uncertain futures, and the familiarization of susceptibility genes.
Gillian Chilibeck, Margaret Lock, Megha Sehdev. Soc Sci Med 2011
26
11

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
Jennifer H Lingler, Meryl A Butters, Amanda L Gentry, Lu Hu, Amanda E Hunsaker, William E Klunk, Meghan K Mattos, Lisa S Parker, J Scott Roberts, Richard Schulz. J Alzheimers Dis 2016
22
13

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Joshua D Grill, Liana G Apostolova, Szofia Bullain, Jeffrey M Burns, Chelsea G Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler,[...]. Alzheimers Res Ther 2017
30
11

Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges.
Bruno Dubois, Alessandro Padovani, Philip Scheltens, Andrea Rossi, Grazia Dell'Agnello. J Alzheimers Dis 2016
170
11

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
José L Molinuevo, Jordi Cami, Xavier Carné, Maria C Carrillo, Jean Georges, Maria B Isaac, Zaven Khachaturian, Scott Y H Kim, John C Morris, Florence Pasquier,[...]. Alzheimers Dement 2016
28
11

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
15
20

The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis.
Gareth J Hollands, David P French, Simon J Griffin, A Toby Prevost, Stephen Sutton, Sarah King, Theresa M Marteau. BMJ 2016
244
11


Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?
Fiona E Matthews, Blossom C M Stephan, Ian G McKeith, John Bond, Carol Brayne. J Am Geriatr Soc 2008
134
7

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.
Ziad S Nasreddine, Natalie A Phillips, Valérie Bédirian, Simon Charbonneau, Victor Whitehead, Isabelle Collin, Jeffrey L Cummings, Howard Chertkow. J Am Geriatr Soc 2005
7

Current and future uses of neuroimaging for cognitively impaired patients.
Gary W Small, Susan Y Bookheimer, Paul M Thompson, Greg M Cole, S-C Huang, Vladimir Kepe, Jorge R Barrio. Lancet Neurol 2008
88
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.